13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01764737 (ClinicalTrials.gov) | December 2012 | 3/1/2013 | Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: VX15/2503;Drug: Placebo | Vaccinex Inc. | PRA Health Sciences | Completed | 18 Years | 60 Years | Both | 50 | Phase 1 | United States |